Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 15/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780227 | 0.93 | EGLN1 (0.38) | EGLN1KDM1AMAOBSLC22A12AKT1 | |
| SCHEMBL3768530 | 0.90 | SLC22A12 (0.38) | EGLN1SLC22A12PTGDR2 | |
| SCHEMBL3781401 | 0.89 | FFAR4 (0.34) | — | |
| SCHEMBL3780101 | 0.89 | MAP4K4 (0.36) | KCNH2 | |
| SCHEMBL3779566 | 0.88 | CYP4F2 (0.32) | KDM1ASLC22A12 | |
| SCHEMBL3780254 | 0.85 | XDH (0.40) | EGLN1SLC22A12AKT1KCNH2 | |
| SCHEMBL3779583 | 0.84 | PDK2 (0.35) | — | |
| SCHEMBL3770733 | 0.83 | SLC22A12 (0.38) | EGLN1KDM1ASLC22A12PTGDR2 | |
| SCHEMBL3767791 | 0.83 | FFAR4 (0.33) | KCNH2 | |
| SCHEMBL3772525 | 0.80 | ABL1 (0.34) | SLC22A12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | EGLN1 3487/4885KDM1A 1957/4885MAOB 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.